Drug delivery for posterior segment eye disease

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 5, 2000, Pages 961-964

  Geroski, Dayle H ^a   Edelhauser, Henry F ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; PILOCARPINE;

CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG PENETRATION; EYE CHAMBER DISEASE; LACRIMAL FLUID; POSTERIOR EYE CHAMBER; PRIORITY JOURNAL; REVIEW;

ANIMALS; CHOROID DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; RETINAL DISEASES;

EID: 0034112393     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Delivery Rev. 1995;16:39-43.
2. Le Bourlais C, Acnar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems - recent advances. Prog Retinal Eye Res. 1998;17:33-58.
3. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985;26:584-587.
4. Ahmed I, Gokhale RD, Shah MV, Patton TF. Physico-chemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci. 1987;76:583-586.
5. Sanborn GE, Anand R, Torti RE. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch Ophthalmol. 1992;110:188-195.
6. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125:237-241.
7. Bill A. Movement of albumin and dextran through the sclera. Arch Ophthalmol. 1965;74:248-252.
8. Barza M, Kane A, Baume JL. Intraocular penetration of gentamicin after subconjunctival and retrobulbar injection Am J Ophthalmol. 1978;85:541-547.
9. Barza M, Kane A, Baume JL. Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit. Am J Ophthalmol. 1977;83:407-413.
10. Wine NA, Gornall AG, Basu PK. The ocular uptake of subconjunctivally injected C14 hydrocortisone. Am J Ophthalmol. 1964;58: 362-366.
11. Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res. 1977;25:577-582.
12. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
13. Rudnick DE, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci. 1999;40:3054-3058.
14. Edwards A, Prausnitz MR. Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. AICHE J. 1998;44:214-225.
15. Miyazaki S, Tkeuchi S, Yokouchi C, Takada M. Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. Chem Pharm Bull. 1984;32:4205-4208.
16. Yu BG, Kwon IC, Kim YH, Han DK, Park KD, Han K, Jeong SY. Development of a local antibiotic delivery system using fibrin glue. J Control Release. 1996;39:65-70.
17. Lee SB, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF. Drug delivery through the sclera: the influence of thickness, hydration, and sustained release systems[ARVO Abstract]. Invest Ophthalmol Vis Sci. 1999;40(4):S83. Abstract nr 438.
18. Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, Kim I, Delori FC, Adamis AP. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
19. Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.